To date, there is not really an answer. Therefore, costeffectivenessof exogenous Epo administration in anemiccirrhotic patients could be attentively considered. In thenear future, further investigations might be designed toanswer these essential questions. From the answers will stemthe assesibility of extending therapeutic options as well asimproving the prognosis of these patients.REFERENCES
Erythropoitin in liver cirrhosis: Two questions without anwers
BRUNO CM;BERTINO, Gaetano;
2005
Abstract
To date, there is not really an answer. Therefore, costeffectivenessof exogenous Epo administration in anemiccirrhotic patients could be attentively considered. In thenear future, further investigations might be designed toanswer these essential questions. From the answers will stemthe assesibility of extending therapeutic options as well asimproving the prognosis of these patients.REFERENCESFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
